Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Nasal and Nasal-type NK/T-cell Lymphoma

National Cancer Centre, SingaporeSmall moleculePhase 4 / ApprovedDormant
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Nasal and Nasal-type NK/T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Mesna
Mingzhi Zhang
Phase 4B

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →